RxDoctor Payments Data

Deborah Stoia

Physician Assistant · Durham, NCNPI 1477896942

Payments from drug & device makers

$10,625in general payments, 2019–2025

Across 604 payments — averaging $17.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
  • Teva Pharmaceuticals USA, Inc.$864
  • Axsome Therapeutics, Inc.$827
  • Johnson & Johnson$759
  • Lundbeck LLC$618
  • plus $5K from 34 others

What the payments were for

  • Food & beverage$10,625100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,625 in reported general payments places this provider in the 95th percentile of 7,441 physician assistant providers in North Carolina.

See all physician assistant providers in North Carolina

Medicare billing

Part B allowed, 2024
$44,769
Medicare patients
55
Services billed
641

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NucyntaTapentadol Hcl34$49,577
Nucynta ErTapentadol Hcl26$46,162
Oxymorphone Hcl ErOxymorphone Hcl39$43,809
OxycontinOxycodone Hcl38$27,805
VraylarCariprazine Hcl11$27,499
RoxicodoneOxycodone Hcl25$27,477
AuvelityDextromethorphan Hbr/Bupropion14$18,890
BelbucaBuprenorphine Hcl23$18,686
Oxycodone Hcl339$17,006
Hydromorphone ErHydromorphone Hcl24$15,133
Oxymorphone Hcl34$11,695
MovantikNaloxegol Oxalate21$9,833
Xtampza ErOxycodone Myristate12$9,816
Hydromorphone Hcl142$9,469
Buprenorphine38$8,872

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Nucynta, Nucynta Er, Belbuca, Xtampza Er$547$124,24295 claims
AbbVieVraylar$1,704$27,49911 claims
Axsome Therapeutics, Inc.Auvelity$827$18,89014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,441 physician assistant providers in North Carolina.

Other physician assistant in Durham

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →